Drugs

Articles

• alkylating agents
  12 March 2006

  alkylators

• NSAIDs
  22 November 2004

  Non-steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory agents (NSAIAs)

• COX inhibitors
  15 April 2005

  Types
  COX-1 inhibitors
  COX-2 inhibitors
  References
  Chan TA. Prostaglandins and the colon cancer connection. Trends Mol Med. 2006 Jun;12(6):240-4. PMID: #16650804#
  Marcus AJ, Broekman MJ, Pinsky DJ. COX inhibitors and thromboregulation. N Engl J Med. 2002 Sep 26;347(13):1025-6. PMID: #12324561#

• zidovudine
  27 January 2005

  Nucleoside analogues can cause a mitochondrial myopathy with RRFs in muscle are nucleoside analogues, such as zidovudine, used in the treatment of certain human immunodeficiencies.
  Nucleoside analogues, after conversion into their active form, inhibit mitochondrial DNA polymerase-gamma and induce mtDNA depletion.
  See also
  nucleoside analogues
  mitochondrial diseases
  oxydative phosphorylation (OXPHOS (...)

• nucleoside analogues
  27 January 2005

  Nucleoside analogues can cause a mitochondrial myopathy with RRFs in muscle are nucleoside analogues, such as zidovudine, used in the treatment of certain human immunodeficiencies.
  Nucleoside analogues, after conversion into their active form, inhibit mitochondrial DNA polymerase-gamma and induce mtDNA depletion.
  See also
  nucleoside analogues
  mitochondrial diseases
  oxydative phosphorylation (OXPHOS (...)

• asparginase
  12 March 2006

  Asparaginase is an enzyme that has been purified from E. coli and Erwinia carotovora. It acts by deaminating extracellular L-asparagine, an amino acid that appears to be essential for protein synthesis by some tumour cells lacking adequate levels of asparagine synthetase.
  Asparaginase from Erwinia carotovora is serologically and biochemically distinct from asparaginase from E. coli, although its antineoplastic activity and toxicity is similar. Asparaginase is usually considered to be cell (...)

• cisplatin
  12 March 2006

  Cisplatin, a platinating agent commonly used to treat several cancers, is associated with nephrotoxicity, neurotoxicity, and ototoxicity, which has hindered its utility.
  Cisplatin is similar to the bifunctional alkylating agents. It covalently binds to DNA and disrupts DNA function. After cisplatin enters the cells, the chloride ligands are replaced by water molecules. This reaction results in the formation of positively charged platinum complexes that react with the nucleophilic sites on (...)

• bleomycin
  8 February 2005

  Pathology
  bleomycin-induced pneumopathy
  bleomycin-induced scleroderma
  References
  Chen J, Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer. 2005 Feb;5(2):102-12. PMID: #15685195#

• platinum
  12 June 2005

  The accidental discovery of the anticancer properties of cisplatin and its clinical introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.
  Although carboplatin—a second-generation analogue that is safer but shows a similar spectrum of activity to cisplatin—was introduced in the 1980s, the pace of further improvements slowed for many years.
  However, in the past several years interest in platinum drugs has increased.
  Key developments include the (...)

• ACEIs
  22 November 2004

  angiotensin-converting enzyme inhibitors

0 | 10 | 20 | 30